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Abstract
INTRODUCTION—The HPTN 052 trial demonstrated that early antiretroviral therapy (ART) 
prevented 93% of HIV transmission events in serodiscordant couples. Some linked infections were 
observed shortly after ART initiation or after virologic failure.
OBJECTIVE—To evaluate factors associated with time to viral suppression and virologic failure 
in participants who initiated ART in HPTN 052.
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METHODS—1,566 participants who had a viral load (VL) >400 copies/mL at enrollment were 
included in the analyses. This included 832 in the early ART arm (CD4 350–550 cells/mm3 at 
ART initiation) and 734 in the delayed ART arm (204 with a CD4 <250 cells/mm3 at ART 
initiation; 530 with any CD4 at ART initiation). Viral suppression was defined as two consecutive 
VLs ≤400 copies/mL after ART initiation; virologic failure was defined as two consecutive VLs 
>1,000 copies/mL >24 weeks after ART initiation.
RESULTS—Overall, 93% of participants achieved viral suppression by 12 months. The annual 
incidence of virologic failure was 3.6%. Virologic outcomes were similar in the two study arms. 
Longer time to viral suppression was associated with younger age, higher VL at ART initiation, 
and region (Africa vs. Asia). Virologic failure was strongly associated with younger age, lower 
educational level, and lack of suppression by 3 months; lower VL and higher CD4 at ART 
initiation were also associated with virologic failure.
CONCLUSIONS—Several clinical and demographic factors were identified that were associated 
with longer time to viral suppression and virologic failure. Recognition of these factors may help 
optimize ART for HIV treatment and prevention.
Keywords
HIV; HPTN 052; early ART; viral suppression; virologic failure; virologic outcomes; HIV 
prevention
INTRODUCTION
The risk of HIV transmission is correlated with HIV viral load.1,2 Effective antiretroviral 
therapy (ART) inhibits viral replication and reduces HIV viral load to low or undetectable 
levels. In the multi-national HIV Prevention Trials Network (HPTN) 052 clinical trial, early 
ART initiation significantly reduced the risk of sexual HIV transmission in serodiscordant 
couples and improved the health of index participants.3,4
Results from HPTN 052 and other studies indicate that sexual transmission of HIV is very 
unlikely when the infected individual is virally suppressed. In HPTN 052, 78 partner 
infections were observed with 1,763 couples followed for >8,500 person-years.4 Genetic 
linkage analysis was performed to determine the likely source of the partner’s infection.5,6 
Over the course of the trial, eight linked infections were diagnosed after the index 
participant started ART.6 Four of those infections occurred close to the time of index ART 
initiation (most likely before the index participant was virally suppressed) and four occurred 
after the index participant failed ART.6,7 Linked partner infections were not observed when 
index participants were stably suppressed on ART. Partner infections have also been 
evaluated in observational studies of serodiscordant couples when the infected individual 
was on ART.8–10 In a prospective cohort study with 168 person-years follow-up, three linked 
infections were observed within 6 months of ART initiation, before the index was virally 
suppressed.11 In an observational study, no linked infections were observed during 1,238 
couple-years of follow up when index participants were virologically suppressed on ART.12
In this report, we evaluated time to viral suppression and virologic failure among index 
participants who started ART in HPTN 052. These studies are relevant to use of ART for 
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HIV prevention, since viremia increases the risk of HIV transmission. The analysis in this 
report includes a comparison of these outcomes in the two study arms of HPTN 052 (early 
vs. delayed ART), and evaluates demographic and clinical factors associated with time to 
viral suppression and virologic failure. These analyses provide new information on clinical 
outcomes in the setting of early ART initiation and use of ART for HIV prevention.
METHODS
Study cohort
The HPTN 052 trial enrolled 1,763 HIV serodiscordant couples (≥18 years of age) at 12 
sites in low- or middle-income countries (Botswana, Kenya, Malawi, South Africa, 
Zimbabwe, India, Thailand, Brazil); two additional couples were enrolled in the United 
States of America (NCT00074581; pilot enrollment from 2005–2007, full enrollment from 
2007–2010). The trial design and results have been reported previously.3,4 Couples were 
randomized to one of two study arms. In the early ART arm, index participants initiated 
ART immediately after enrollment (CD4 cell count between 350–550 cells/mm3 ). In the 
delayed ART arm, ART was initiated after the CD4 cell count fell below 250 cells/mm3 on 
two consecutive study visits, or when the index participant developed an AIDS-defining 
illness. At enrollment, HIV-infected index participants reported no prior ARV drug use with 
the exception of short-term ARV drug use for prevention of mother-to-child transmission. 
However, retrospective ARV drug testing revealed that some participants were on ART at the 
time of study enrollment.13 The most common ART regimen was a combination of efavirenz 
(EFV), lamivudine (3TC), and zidovudine (ZDV); other drugs used for treatment included 
atazanavir, atazanavir/ritonavir, emtricitabine, lopinavir/ritonavir (LPV/r), nevirapine, 
stavudine, and tenofovir disoproxil fumarate.3 The analyses in this report include data from 
the start of the trial through May, 2015 (end of study). In May 2011, participants were 
informed of interim study results that demonstrated that early ART prevented 96% of linked 
HIV transmissions.3 After that date, all study participants were counseled on the personal 
and public health benefits of early ART, and ART was offered to all index participants 
regardless of CD4 cell count. In this report, virologic outcomes were evaluated in 
participants in the early and delayed ART arms. Participants in the delayed ART arm were 
also stratified into two groups based on whether they started ART before or after release of 
interim study results. Participants who had a viral load <400 copies/mL at study enrollment 
were excluded from analysis.
Laboratory and statistical methods
HIV viral load and CD4 cell count assays were performed at study sites.3 Prior to November 
2006, viral load testing was performed quarterly after ART initiation. Follow-up visits were 
allowed to occur within a 2-week window of the targeted visit dates. After November 2006, 
viral load testing was performed at an additional visit one month after ART initiation. The 
majority of participants were enrolled after this date and had a 1-month visit. Additional 
study visits with viral load assessments were permitted at the discretion of site investigators 
for clinical management of participants on ART. Viral suppression was defined as the first of 
two consecutive viral load measurements ≤400 copies/mL after ART initiation. Virologic 
failure was defined as the first of two consecutive viral load measurements >1,000 
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copies/mL after 24 weeks on ART. Potential ascertainment bias in determining the timing of 
a viral suppression due to variation in the timing of viral load measurements (interval 
censorship) was examined. Characteristics of study participants in different groups (early 
ART arm; delayed ART arm; delayed ART arm with ART initiation before vs. after May 
2011) were analyzed using the Chi-square test (for categorical variables) and the Wilcoxon 
rank sum test (for continuous variables). Cox regression and Kaplan-Meier methods were 
used to analyze the association of demographic and other factors with time to viral 
suppression and virologic failure. The multivariate Cox regression model was created using 
a backward model selection method; p<0.05 was used to exclude variables in the backward 
selection model.
Ethical considerations
Institutional Review Boards/Ethics Committees at each participating institution approved the 
HPTN 052 trial. Written informed consent was obtained from all study participants.
RESULTS
Study cohort
We evaluated viral suppression and virologic failure outcomes in 1,566 index participants in 
HPTN 052 who had a viral load >400 copies/ml at study enrollment and initiated ART 
(Figure 1). Table 1 shows demographic and clinical characteristics of study participants at 
the time of ART initiation. At ART initiation, the median CD4 cell count was 439 cells/mm3 
in the early ART arm and 314 cells/mm3 in the delayed ART arm. At the time of ART 
initiation, index participants in the early ART arm were younger and had higher CD4 cell 
counts and lower viral loads; they were also more likely to receive EFV/3TC/ZDV than 
other regimens, have a lower educational status, and have >1 sexual partner compared to 
participants in the delayed ART arm. In the delayed ART arm, index participants who started 
ART before release of interim study results in May 2011 had lower CD4 cell counts and 
higher viral loads at ART initiation; those participants also had a different regional 
distribution and were more likely to be male compared to index participants in the delayed 
ART arm who started ART after May 2011 (Table 1).
Analysis of viral suppression after ART initiation
Viral suppression was evaluated in 1,566 index participants (7,397 person-years of follow up 
on ART): 832 in the early ART arm and 734 in the delayed ART arm (Figure 1). In the 
delayed ART arm, 204 participants initiated ART before May 2011 and 530 initiated ART 
after May 2011 (Figure 1). Overall, 93% of the participants achieved viral suppression by 12 
months after ART initiation. At 1, 3, 6, 9 and 12 months after ART initiation, the cumulative 
probabilities of viral suppression were 49%, 83%, 89%, 91%, and 92% in the early ART 
arm; 25%, 72%, 92%, 95%, and 96% in the delayed ART arm among participants who 
initiated ART before May 2011; and 43%, 77%, 87%, 90%, and 93% in the delayed ART 
arm among participants who initiated ART after May 2011.
In Kaplan-Meier analysis, there was no significant difference in time to viral suppression 
among participants in the following three groups: early ART arm; delayed ART arm with 
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ART initiation before May 2011; delayed ART with ART initiation after May 2011 (p=0.08, 
Figure 2A). Some differences were noted in the timing of viral load measurements in these 
three participant groups. More detailed analyses indicated that these differences were not 
likely to have impacted the analysis of time to viral suppression in these groups 
(Supplemental File 1). There was no difference in time to viral suppression between the two 
study arms (Table 2). Time to viral suppression was longer among participants in the 
delayed ART arm who initiated ART before May 2011 than in the early ART arm, but this 
difference was not statistically significant in the multivariate model (Table 2). In univariate 
analyses, the following variables were associated with a longer time to viral suppression: 
younger age, lower CD4 cell count at ART initiation, higher viral load at ART initiation, 
region, and regimen. However, only three of these factors were associated with longer time 
to viral suppression in the multivariate model: younger age (<25 years), higher viral load at 
ART initiation, and region (Africa, compared to Asia, Table 2). Kaplan-Meier plots were 
used to assess the proportional hazards assumption for these three variables (Supplemental 
File 2A); the plots indicate that the proportional hazards assumption is appropriate for the 
Cox model.
Analysis of virologic failure
Virologic failure was evaluated in 1,528 index participants with 6,662 person-years of follow 
up on ART (Figure 1). The annual incidence of virologic failure was 3.6% (95% confidence 
intervals [CI]: 3.1%–4.1%) overall; 3.4% (95% CI: 2.9%–4.0%) in the early ART arm, and 
3.8% (95% CI: 3.1%–4.7%) in the delayed ART arm (p=0.37). In the delayed ART arm, the 
annual incidence of virologic failure was 2.9% (95% CI: 1.9%–4.3%) among participants 
who initiated ART before May 2011 and 4.4% (95% CI: 3.4%–5.6%) among participants 
who initiated ART after May 2011 (p=0.08).
In Kaplan-Meier analysis, there was no significant difference in virologic failure among 
participants in the three study groups described above (p=0.32, Figure 2B). In univariate 
analyses, there was also no significant difference in virologic failure in the early vs. delayed 
ART arms or in the early ART arm compared to either delayed ART group (before vs. after 
May 2011, Table 3). Other factors were associated with a higher risk of virologic failure, 
including younger age (<25 years), female gender, higher CD4 cell count at ART initiation, 
lower education level, marital status (married), and lack of viral suppression by 3 months. 
All of these variables were independently associated with virologic failure in the 
multivariate model with the exception of gender. In addition, lower viral load at ART 
initiation was associated with virologic failure in the multivariate model (Table 3). Kaplan-
Meier plots were used to assess the proportional hazards assumption for variables that were 
associated with virologic failure in the multivariate model (see Supplemental File 2B); the 
plots indicate that the proportional hazards assumption is appropriate for the Cox model.
Overall (in both study arms), only 16 (6.7%) of the 238 virologic failures occurred after four 
years on ART. To explore whether the findings were affected by late failure events, the 
analysis shown in Table 3 was repeated using the same methods after censoring data from 
study visits more than 4 years after ART initiation. In the multivariate model that included 
censoring, the same variables were significantly associated with virologic failure with the 
Eshleman et al. Page 7













exception of CD4 cell count. Furthermore, the hazard ratios for all variables analyzed were 
similar with and without censoring; the p-values for these variables were similar with and 
without censoring with one exception: the p-value for viral load at ART initiation was lower 
with censoring (p=0.0035).
DISCUSSION
Achieving and maintaining viral suppression after ART initiation directly benefits those on 
ART and has public health benefits by reducing HIV transmission.4,14 The HPTN 052 trial 
identified two risk periods for HIV transmission when ART is used for HIV prevention: near 
the time of ART initiation (before the index was virally suppressed) and after virologic 
failure (when the index was viremic).6 Overall, 93% of the participants included in this 
report were virally suppressed by 12 months after ART initiation. The time to viral 
suppression was similar between the two study arms (early ART arm vs. delayed ART arm, 
p=0.06). We did observe a longer time to viral suppression for participants in the delayed 
ART arm who initiated ART before May 2011, compared to those in the early ART arm 
(p=0.038, univariate analysis); this subset of participants in the delayed ART arm started 
ART at lower CD4 cell counts than the participants in the other two groups (early ART arm, 
delayed ART arm with ART initiation after May 2011). This difference was not observed in 
the multivariate model where the analysis was adjusted for other factors. There was also no 
significant difference when time to viral suppression was compared across all three 
participant groups (p=0.095). CD4 cell count at ART initiation was highly associated with 
time to viral suppression in the univariate model, but was not significantly associated with 
time to viral suppression in the multivariate model that adjusted for other variables.
In this cohort, three factors were independently associated with longer time to viral 
suppression: higher viral load at ART initiation, younger age (<25 years), and geographic 
region (Africa compared to Asia). Higher viral load at ART initiation was also associated 
with a longer time to viral suppression in studies where ART was initiated at lower CD4 cell 
counts.15 Younger age has been associated with lack of viral suppression16,17 and poor ART 
adherence18,19 in previous studies. In HPTN 052, self-reported ART adherence was higher 
among older participants in the early ART arm, but this association was not statistically 
significant in multivariate analysis.20 The regional differences in time to viral suppression 
observed in HPTN 052 may reflect differences in HIV subtype or other factors, such as 
adherence. Regional differences in adherence were observed in the early ART arm in HPTN 
052.20 Previous studies have reported more rapid viral suppression in individuals with 
certain HIV subtypes.21,22
We did not find an association between ART regimen (EFV/3TC/ZDV vs. other) and time to 
viral suppression in HPTN 052. Other studies have demonstrated that the rate of viral load 
decline varies with different ARV drug regimens.23,24 For example, shorter time to viral 
suppression has been observed using EFV-based ART compared to LPV/r-based ART25 and 
with regimens that include an HIV integrase strand transfer inhibitor (INSTI).26,27 In HPTN 
052, 72% of the index participants on ART were on EFV/3TC/ZDV; the remaining 
participants were on a variety of different ART regimens;3 none received an INSTI-based 
regimen.
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Among the HPTN 052 participants in this report, virologic failure was uncommon, with an 
annual incidence of 3.6%. Three factors were strongly associated with virologic failure in 
multivariate analyses: younger age (<25 years, compared to ≥40 years), a lower level of 
education, and lack of viral suppression by 3 months; lower viral load and higher CD4 cell 
count at ART initiation were also associated with virologic failure. An association between 
younger age and virologic failure was observed in a previous study.28 An association 
between lower educational level and virologic failure was not observed in previous studies 
performed in the US and Southern Africa;29,30 further studies are needed to determine 
whether the association observed in this study is due to lower adherence or other factors. We 
did observe a weak association between a higher CD4 cell count at ART initiation and 
virologic failure. A possible explanation for this finding is that participants who had higher 
CD4 cell counts at the time of ART initiation may have had lower adherence to ART 
because they were in better health. Of note, the incidence of virologic failure was similar in 
the two study arms in the interim analysis of the HPTN 052 trial (data through February 
2011)3 and in this extended analysis (data through May 2015). This may have reflected the 
fact that the interim analysis included a shorter follow-up period with fewer virologic failure 
events, and that in the extended analysis, the delayed ART arm included two distinct 
participant groups: (1) before May 2011, participants initiated ART when their CD4 cell 
count fell below 250 cells/mm3 or they developed an AIDS defined illness; (2) after May 
2011, participants started ART at higher CD4 cell counts and were aware of the benefits of 
early ART. Interestingly, participants in the latter group had a higher annual incidence of 
virologic failure than those who started ART before May 2011 (2.9% vs. 4.4%, p=0.08). 
This indicates that knowledge of the beneficial effects of early ART did not improve 
treatment outcomes.
Other studies have shown that HIV subtype is associated with virologic failure. HIV 
subtypes were not available for all participants in this study; however the prevalent HIV 
subtypes are different in the Americas (mostly B and F in Brazil), Africa (mostly C in sub-
Saharan Africa). In the ACTG 5175 study (PEARLS), which was performed at many of the 
same study sites as HPTN 052, subtype C infection was associated with a higher rate of 
virologic failure compared to subtype B infection.31 The frequency of ART failure was also 
higher in subtype C compared to subtype B in a cohort study from Sweden.32
The findings from HPTN 052 and other studies provide strong support for universal HIV 
treatment where HIV-infected individuals are eligible to start ART early regardless of CD4 
cell count,4,33 which is now recommended for all HIV-infected individuals.34 Community 
randomized trials are underway to determine the best way to deliver universal ART and 
assess the impact of universal ART on HIV incidence at a population level. Additional 
interventions (e.g., use of pre-exposure prophylaxis in couples at the start of ART until viral 
suppression is well-established, and use of INSTI-based ART regimens) may help reduce 
transmission risk. This study identified several clinical and demographic factors associated 
with time to viral suppression after ART initiation and virologic failure. Recognition of 
these factors may help to optimize ART for HIV treatment and prevention.
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Study cohort for virologic outcomes analysis.
The figure shows the number of participants in the early ART arm and delayed ART arm 
(stratified by whether or not ART was initiated before or after May, 2011) included in the 
analyses of viral suppression and virologic failure. Abbreviations: ART: antiretroviral 
therapy, VL: viral load; c/mL: copies/milliliter.
a The 1,566 participants included in the viral suppression analysis were followed for 4722.4 
person-years in the early ART arm and 2674.8 person-years in the delayed ART arm (977.4 
person-years in the delayed ART arm before May, 2011 and 1697.4 person-years in the 
delayed ART arm after May, 2011).
b The 1,528 participants included in the virologic failure analysis were followed for 4216.1 
person-years in the early ART arm and 2445.8 person-years in the delayed ART arm (893.1 
person-years in the delayed ART arm before May, 2011 and 1552.7 person-years in the 
delayed ART arm after May, 2011).
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Kaplan-Meier estimates for virologic outcomes after ART initiation by study group.
Kaplan-Meier plots show the relationship of study group (early ART arm, delayed ART arm 
with ART initiation before May 2011, and delayed ART arm with ART initiation after May 
2011) with time to viral suppression (Panel A) and virologic failure (Panel B) after ART 
initiation. The numbers below each graph show the number of participants who were at risk 
of viral suppression or virologic failure at each time point.
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Abbreviations: ART: antiretroviral therapy; c/mL: copies/milliliter.
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